Review
Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS
Affiliations
- PMID: 17668369
Item in Clipboard
Review
Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS
Curr Opin Investig Drugs.
2007 Aug.
Abstract
Pfizer Inc is developing maraviroc, a CCR5 receptor antagonist for the treatment of HIV-1 infection and rheumatoid arthritis. In April 2007, the FDA advisory committee voted to approve maraviroc for HIV-1 infection. Phase II and III clinical trials, and post-approval studies are ongoing in both treatment-experienced and -naive HIV patients. Phase II trials have also been initiated in patients with rheumatoid arthritis.
Similar articles
-
Treatment of HIV infection with the CCR5 antagonist maraviroc.Expert Opin Pharmacother. 2010 May;11(7):1215-23. doi: 10.1517/14656561003801081. Expert Opin Pharmacother. 2010. PMID: 20402558 Review.
-
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32. doi: 10.1128/AAC.49.11.4721-4732.2005. Antimicrob Agents Chemother. 2005. PMID: 16251317 Free PMC article.
-
CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.Eur J Med Res. 2007 Oct 15;12(9):409-17. Eur J Med Res. 2007. PMID: 17933722 Review.
-
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.Clin Pharmacol Ther. 2005 Nov;78(5):508-19. doi: 10.1016/j.clpt.2005.07.010. Epub 2005 Sep 28. Clin Pharmacol Ther. 2005. PMID: 16321617 Clinical Trial.
-
How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.Eur J Med Res. 2007 Oct 15;12(9):435-40. Eur J Med Res. 2007. PMID: 17933725 Review.
Cited by
-
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).Antimicrob Agents Chemother. 2008 Mar;52(3):858-65. doi: 10.1128/AAC.00821-07. Epub 2007 Dec 10. Antimicrob Agents Chemother. 2008. PMID: 18070967 Free PMC article. Clinical Trial.
-
Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1.J Med Chem. 2012 May 24;55(10):4764-75. doi: 10.1021/jm3002247. Epub 2012 May 10. J Med Chem. 2012. PMID: 22524483 Free PMC article.
-
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.Arthritis Res Ther. 2012 Jan 17;14(1):R11. doi: 10.1186/ar3685. Arthritis Res Ther. 2012. PMID: 22251436 Free PMC article. Clinical Trial.
-
Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.Antimicrob Agents Chemother. 2010 Feb;54(2):734-41. doi: 10.1128/AAC.00841-09. Epub 2009 Dec 7. Antimicrob Agents Chemother. 2010. PMID: 19995923 Free PMC article.
-
Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors.Bioorg Med Chem. 2021 Feb 15;32:116000. doi: 10.1016/j.bmc.2021.116000. Epub 2021 Jan 8. Bioorg Med Chem. 2021. PMID: 33461144 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous